ASX-listed healthcare technology company Lifespot Health is planning to conduct extensive clinical trials in 2021 to meet the TGA safety and efficacy standards required for medical registration of its combined medical inhaler/cannabinoid e-liquid products.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

Join or login

Lifespot Health CEO Matthew Golden said he expects the trials will demonstrate greater cost effectiveness for patients and could lead to CBD vapes being available over the counter at pharmacies in the foreseeable future.

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...